-Charles S Fuchs Researcher Activity Profile

Research Author Detailed Information 

Charles S Fuchs Publication Rate By Year

Charles S Fuchs has published 8 paper(s) in 2006, 37 paper(s) in 2007, 8 paper(s) in 2008, for a total of 53 research publications in total.

Charles S Cs Fuchs Author Information

LAST NAME: fuchs

FIRST NAME: Charles S

INITIALS: cs

AFFILIATION:

Papers

Charles S Fuchs's Publication Record

1. Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Year Published: 2007
Division of Chronic Disease Surveillance, Korea Centers for Disease Control and Prevention, Seoul, Korea.
2. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
3. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Year Published: 2006
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA.
4. Cardiovascular risk factors for physician-diagnosed lumbar disc herniation. Year Published: 2006
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. bjhawar@sympatico.ca
5. The role of targeted therapy in the treatment of colorectal cancer. Year Published: 2006
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
6. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Year Published: 2006
Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA.
7. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Year Published: 2006
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. shuji_ogino@dfci.harvard.edu
8. Hormone replacement therapy and survival after colorectal cancer diagnosis. Year Published: 2006
Dana-Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA. jang@partners.org
9. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Year Published: 2006
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA. azhu@partners.org
10. Dietary carotenoids and risk of colorectal cancer in a pooled analysis of 11 cohort studies. Year Published: 2007
National Public Health Institute, Helsinki, Finland.
11. Long-term aspirin use and mortality in women. Year Published: 2007
Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 0214, USA.
12. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Year Published: 2007
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. dmichaud@hsph.harvard.edu
13. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
14. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
15. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. bwolpin@partners.org
16. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
17. Adjuvant and neoadjuvant approaches in gastric cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. kng4@partners.org
18. Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. Year Published: 2007
Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. ahazra@hsph.harvard.edu
19. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. Year Published: 2007
Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Bldg 2, Boston, MA 02115, USA. kana.wu@channing.harvard.edu
20. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
21. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Year Published: 2007
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. azhu@partners.org
22. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
23. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Year Published: 2007
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. dy.grace@mayo.edu
24. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
25. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, MA 02115, USA. bwolpin@partners.org
26. Dietary choline and betaine and the risk of distal colorectal adenoma in women. Year Published: 2007
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA. eunyoung.cho@channing.harvard.edu
27. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. jmeyerhardt@partners.org
28. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
29. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. Year Published: 2007
Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.
30. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
31. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. Year Published: 2007
Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. anita.koushik@umontreal.ca
32. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Year Published: 2007
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. dmichaud@hsph.harvard.edu
33. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis St, BWH Pathology, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
34. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
35. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Year Published: 2007
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. azhu@partners.org
36. IGFBP3 Promoter Methylation in Colorectal Cancer: Relationship with Microsatellite Instability, CpG Island Methylator Phenotype, and p53. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
37. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
38. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
39. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
40. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
41. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu
42. Long-term aspirin use and mortality in women. Year Published: 2007
Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 0214, USA.
43. Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA, 02115, USA, jmeyerhardt@partners.org.
44. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Year Published: 2007
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. dmichaud@hsph.harvard.edu
45. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Year Published: 2008
[1] 1Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA [2] 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
46. Adjuvant and neoadjuvant approaches in gastric cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. kng4@partners.org
47. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. Year Published: 2008
48. Aspirin dose and duration of use and risk of colorectal cancer in men. Year Published: 2008
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
49. The role of targeted therapy in the treatment of colorectal cancer. Year Published: 2006
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
50. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. charles_fuchs@dfci.harvard.edu
51. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. Year Published: 2008
52. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
53. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. shuji_ogino@dfci.harvard.edu